Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
about
Considerations for the prediction of survival time in pancreatic cancer based on registry data.Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule?Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer.Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumabSystemic therapy for metastatic pancreatic adenocarcinoma.Pancreas cancer survival in the gemcitabine eraPoxvirus-based vaccine therapy for patients with advanced pancreatic cancer.Recent advances in targeted therapy for non-small cell lung cancer.Role of bevacizumab for the treatment of non-small-cell lung cancer.Erlotinib in non-small-cell lung cancer.Quality of life in pancreatic cancer: analysis by stage and treatment.A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma.A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis.Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients: a single institute experience.Response to Drs Von Hoff and RenschlerHow I treat pancreatic ductal adenocarcinoma.Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer.
P2860
Q30654731-3E70BC6E-F20C-4018-82DC-F7A3C3FF3A30Q33376655-0B23BC91-A1B7-43B3-B0FC-7D2BEC8EA5FDQ33378968-7CD9E9FC-E529-46F2-8FFA-00FE6CFDA882Q33402401-A51370B2-7BBC-4F6A-BDBA-7FD7699CC141Q33402598-3C186093-16FF-44EC-818B-3DB0E01624E3Q33887648-2112B826-DEF5-4023-A2E8-172B8441C981Q34694813-191B2075-7015-4112-B8B2-B1504CA8F2A1Q35076238-BE444149-7458-42D4-BE28-44842C275286Q35181008-191076CA-B190-4F21-9DB1-5ECEED3E5EABQ36412657-01D3A28B-F300-4070-AD7C-0464C75DDFBFQ36709566-2EA427BB-940A-4920-9D53-BC25F90B9655Q36768282-9999C706-35AF-4FF4-B649-26C8C5349C6CQ36968183-9EDD2688-C953-4BCD-85BF-9C201D58462CQ37249715-4F87CD9B-F037-40AC-93ED-01BC08405B00Q37508315-1BB27222-D264-4126-A3FB-88FD4B3A8179Q37632164-A1B43635-1A51-47F8-A542-A5BAAE6FEB1EQ40345312-56B62A3D-6D66-4FBC-8B37-2751D64D9365Q41027512-68A9E84A-AEFB-4B51-A724-16A0B846A1D6Q42227453-D672A346-8521-4460-9716-64470755B1DCQ42953117-02DF7830-7DDE-44A7-AD36-48706D037A4CQ44916594-91908FC8-D62E-4F40-A18D-F4C207B95BBBQ47635827-88767FAF-C70A-4FEE-B33E-7AA792156832
P2860
Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Phase II study of fixed dose r ...... denocarcinoma of the pancreas.
@ast
Phase II study of fixed dose r ...... denocarcinoma of the pancreas.
@en
type
label
Phase II study of fixed dose r ...... denocarcinoma of the pancreas.
@ast
Phase II study of fixed dose r ...... denocarcinoma of the pancreas.
@en
prefLabel
Phase II study of fixed dose r ...... denocarcinoma of the pancreas.
@ast
Phase II study of fixed dose r ...... denocarcinoma of the pancreas.
@en
P2093
P356
P1476
Phase II study of fixed dose r ...... denocarcinoma of the pancreas.
@en
P2093
Alan P Venook
Andrew H Ko
Brian Schillinger
Elizabeth Dito
Emily K Bergsland
Margaret A Tempero
P304
P356
10.1200/JCO.2005.01.8267
P407
P577
2005-12-12T00:00:00Z